Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11197967 | 0.89 | ALDH1A1 (0.47) | ALDH1A1MAPTPOLBHTTSMN1; SMN2 | |
| SCHEMBL6179650 | 0.80 | — | — | |
| SCHEMBL48559 | 0.80 | SLC6A4 (0.41) | ALDH1A1EPHX1SMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL8224831 | 0.79 | ALDH1A1 (0.41) | ALDH1A1MAPTPOLBHTTSMN1; SMN2 | |
| SCHEMBL18844900 | 0.78 | EPHX1 (0.35) | EPHX1SLC6A4 | |
| Ammonia Solution, Strong SCHEMBL2966175 | 0.78 | SLC6A4 (0.40) | ALDH1A1EPHX1SMN1; SMN2GAAL3MBTL1 | |
| SCHEMBL172339 | 0.76 | EPHX1 (0.50) | ALDH1A1EPHX1HTTGAAL3MBTL1 | |
| SCHEMBL16937601 | 0.76 | EPHX1 (0.50) | ALDH1A1EPHX1HTTGAAL3MBTL1 | |
| SCHEMBL14620500 | 0.76 | — | — | |
| SCHEMBL172729 | 0.76 | EPHX1 (0.50) | ALDH1A1EPHX1HTTGAAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9090651-B2 | Helix 12 directed pharmaceutical products | ENDORECHERCHE, INC. (CA) | 2015-07-28 | — | — | US | disclosed |
| US-9090651-B2 | Helix 12 directed pharmaceutical products | ENDORECHERCHE, INC. (CA) | 2015-07-28 | — | — | US | disclosed |
| US-8168627-B2 | Helix 12 directed non-steroidal antiandrogens | ENDORECHERCHE, INC. (CA) | 2012-05-01 | — | — | US | disclosed |
| US-8168627-B2 | Helix 12 directed non-steroidal antiandrogens | ENDORECHERCHE, INC. (CA) | 2012-05-01 | — | — | US | disclosed |
| US-20100227855-A1 | HELIX 12 DIRECTED NON-STEROIDAL ANTIANDROGENS | ENDORECHERCHE, INC. (CA) | 2010-09-09 | — | — | US | disclosed |
| US-20100227855-A1 | HELIX 12 DIRECTED NON-STEROIDAL ANTIANDROGENS | ENDORECHERCHE, INC. (CA) | 2010-09-09 | — | — | US | disclosed |
| US-7709516-B2 | Helix 12 directed non-steroidal antiandrogens | ENDORECHERCHE, INC. (CA) | 2010-05-04 | — | — | US | disclosed |
| US-7709516-B2 | Helix 12 directed non-steroidal antiandrogens | ENDORECHERCHE, INC. (CA) | 2010-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227855-A1 | HELIX 12 DIRECTED NON-STEROIDAL ANTIANDROGENS | AR, SHBG, CYP17A1 | ALDH1A1 1718/4885MAPT 1110/4885EPHX1 3344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.